Labopharm Inc.

Labopharm Inc.

Labopharm Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies. It offers once-daily formulation of the analgesic tramadol under the RYZOLT brand name for the treatment of severe chronic pain in adults. The company sells RYZOLT primarily in the United States, Europe, Canada, South Korea, and Australia. Labopharm's products in pipeline include once-daily formulation of trazodone, a serotonin antagonist reuptake inhibitor for the treatment of depressive disorder. Its product candidates in clinical development based on Contramid platform comprise twice-daily formulation of tramadol plus acetaminophen to address acute pain; and Abuse Deterrent Platform to provide safer medications through resistance to the uncontrolled release of the active ingredient after actions, such as breaking, chewing, crushing and heating, or consumption with alcohol. Its product candidates in clinical development based on the Polymeric Nano-Delivery System platform comprise lipid-and preservative-free formulation of the intravenous anaesthetic agent propofol; and SN-38, which is the active metabolite in the prescribed intravenous colon cancer drug irinotecan.

Contact Details

Office Address

Labopharm Inc.
480 Armand-Frappier Blvd.
Laval, Québec, Canada H7V4B4
Phone: (450) 686-1017
Fax: (450) 686-9141

Executives

Chief Exec. Officer

Mr. James R. Howard-Tripp

Chief Financial Officer and Sr. VP

Mr. Mark A. D'Souza

Business Reviews for Labopharm Inc.

Related Companies